Tafamidis, Tafamidis Meglumine and Vicks DayQuil Multi-Symptom Cold/Flu Relief
Determining the interaction of Tafamidis, Tafamidis Meglumine and Vicks DayQuil Multi-Symptom Cold/Flu Relief and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein. MANAGEMENT: Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects. References Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]): "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group, New York, NY. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations. The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.
MANAGEMENT: Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare "Centro de información online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
- "Product Information. Vyndaqel (tafamidis)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: tafamidis
Brand name: Vyndamax, Vyndaqel
Synonyms: Tafamidis
Generic Name: acetaminophen / dextromethorphan / phenylephrine
Brand name: Comtrex Cold & Cough, DayQuil Cold & Flu, Daytime, Flu & Severe Cold & Cough Daytime Powder, Mapap Cold Formula, Robitussin Peak Cold Daytime Cold + Flu, Sudafed PE Pressure+Pain+Cough, Theraflu Daytime Severe Cold & Cough, Theraflu Warming Severe Cold Daytime, Tylenol Cold Multi-Symptom Daytime, Vicks Dayquil Liquicaps Cold/Flu, Contac Complete Cough, Cold & Flu Extra Strength, Tylenol Cold Daytime, Neocitran Non Drowsy Extra Strength Cold and Flu, Tylenol Cold Daytime Extra Strength, Tylenol Flu Daytime Extra Strength, Theraflu Nighttime Severe Cold & Cough, Theraflu Warming Relief Daytime Multi-Symptom Cold, Tylenol Children's Plus Cold & Cough, Theraflu Multi-Symptom Severe Cold, Day Time Cold & Flu, DayQuil Nature Fusion Cold & Flu, Theraflu ExpressMax Day Cold & Cough, Tylenol Cold Max Day, Mucinex Fast-Max Severe Cold and Sinus, Mucinex Fast-Max Congestion and Headache, Theraflu PowerPods Daytime Severe Cold, Comtrex Cold and Cough Maximum Strength, Vicks DayQuil Multi-Symptom Cold/Flu Relief
Synonyms: DayQuil Cold & Flu
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Tafamidis, Tafamidis Meglumine-Vicks DayQuil Severe Cold/Flu
- Tafamidis, Tafamidis Meglumine-Vicks DayQuil Sinex
- Tafamidis, Tafamidis Meglumine-Vicks Formula 44
- Tafamidis, Tafamidis Meglumine-Vicks Formula 44 Custom Care Cough/Cold PM
- Tafamidis, Tafamidis Meglumine-Vicks Formula 44 D Cough
- Tafamidis, Tafamidis Meglumine-Vicks NyQuil Multi-Symptom
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafenoquine
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafenoquine (Malaria Prevention)
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafenoquine (Prevention of Malaria Relapse)
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafenoquine Succinate (Arakoda)
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafenoquine Succinate (Krintafel)
- Vicks DayQuil Multi-Symptom Cold/Flu Relief-Tafinlar